Drug Metabolism by Leukocytes and Its Role in Drug-Induced Lupus and Other Idiosyncratic Drug Reactions

References

• Wallerstein R. O., Condit P. K., Kasper C. K., Brown J. W., Morrison F. R. Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA 1969; 208: 2045
   PubMed Web of Science ®Google Scholar
• Polak B. C. P., Wesseling H., Schut D., Herxheimer A., Meyler L. Blood dyscrasias attributed to chloramphenicol: a review of 576 published and unpublished cases. Acta Med. Scand. 1972; 192: 409
   PubMed Web of Science ®Google Scholar
• Pinsky P. F., Hurwitz E. S., Schonberger L. B., Gunn W. J. Reye's syndrome and aspirin: evidence for a dose-response effect. JAMA 1988; 260: 657
   PubMedGoogle Scholar
• Waldman R. J., Hall W. N., McGee H., Van Amburg G. Aspirin as a risk factor in Reye's syndrome. JAMA 1982; 247: 3089
   PubMed Web of Science ®Google Scholar
• Pullen H., Wright N., Murdoch J. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet 1967; 2: 1176
   PubMed Web of Science ®Google Scholar
• Fischl M. A., Dickinson G. M., La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis forPneumocystis carinii pneumonia in AIDS. JAMA 1988; 259: 1185
   PubMed Web of Science ®Google Scholar
• Parker C. W. Allergic reactions in man. Pharmacol. Rev. 1982; 34: 85
   PubMed Web of Science ®Google Scholar
• Seaman W. E., Ishak K. G., Plotz P. H. Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann. Intern. Med. 1974; 80: 1
   PubMed Web of Science ®Google Scholar
• Seaman W. E., Plotz P. H. Effect of aspirin on liver tests in patients with RA or SLE and in normal volunteers. Arthritis Rheum. 1976; 19: 155
   PubMed Web of Science ®Google Scholar
• Coombs R. R. A., Gell P. G. H. The classification of allergic reactions underlying disease. Clinical Aspects of Immunology, P. G. H. Gell, R. R. A. Coombs. Blackwell Scientific Publications, Oxford 1963; 317
   Google Scholar
• Park B. K., Coleman J. W., Kitteringham N. R. Drug disposition and drug hypersensitivity. Biochem. Pharmacol. 1987; 36: 581
   PubMed Web of Science ®Google Scholar
• Pohl L. R., Satoh H., Christ D. D., Kenna J. G. The immunologic and metabolic basis of drug hypersensitivities. Annu. Rev. Pharmacol. 1988; 28: 367
   Google Scholar
• Unanue E. R., Allen P. M. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 1987; 236: 551
   PubMed Web of Science ®Google Scholar
• Petz L. D., Fudenberg H. H. Immunologic mechanisms in drug-induced cytopenias. Prog. Hematol. 1975; 9: 185
   PubMedGoogle Scholar
• Vergani D., Mieli-Vergani G., Alberti A., Neuberger J., Eddleston A., Davis M., Williams R. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med. 1980; 303: 66
   PubMed Web of Science ®Google Scholar
• Kenna J. G., Neuberger J., Williams R. Evidence for the expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis. Hepatology 1988; 8: 1635
   PubMed Web of Science ®Google Scholar
• Kenna J. G., Satoh H., Christ D. D., Pohl L. R. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol. Exp. Ther. 1988; 245: 1103
   PubMed Web of Science ®Google Scholar
• McLain G. E., Sipes I. G., Brown B. R. An animal model of halothane hepatotoxicity. Anesthesiology 1979; 51: 321
   PubMed Web of Science ®Google Scholar
• Moult P. J. A., Sherlock S. Halothane related hepatitis. A clinical study of 26 cases. Q. J. Med. 1975; 44: 99
   PubMedGoogle Scholar
• Arroyave C. M., Bhat K. N., Crown R. Activation of the alternative pathway of the complement system by radiographic contrast media. J. Immunol. 1976; 117: 1866
   PubMedGoogle Scholar
• Kolb W. P., Lang J. H., Lasser E. C. Nonimmunologic complement activation in normal human serum induced by radiographic contrast media. J. Immunol. 1978; 121: 1232
   PubMedGoogle Scholar
• Von Zabern I., Przyklenk H., Vogt W., Sachsenheimer W. The effect of radiographic contrast media on complement components C3 and C4: generation of C3b-like C3 and C4b-like C4. Int. J. Im-munopharmac. 1983; 5: 503
   PubMedGoogle Scholar
• Sim E., Law S. A. Hydralazine binds covalently to complement component C4: different reactivity of C4A and C4B gene products. FEBS. Lett. 1985; 184: 323
   PubMed Web of Science ®Google Scholar
• Sim E., Stanley L., Gill E. W., Jones A. Metabolites of procainamide and practolol inhibit complement components C3 and C4. Biochem. J. 1988; 251: 323
   PubMed Web of Science ®Google Scholar
• Sim E., Gui E. W., Sim R. B. Drugs that induce systemic lupus erythematosus inhibit complement component C4. Lancet 1984; 2: 422
   PubMedGoogle Scholar
• American Medical Association. Drug Evaluations. W. B. Saunders, Philadelphia 1986; 1154
   Google Scholar
• Sorrell T. C., Forbes I. J., Burness F. R., Rischbieth R. H. C. Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin). Lancet 1971; 2: 1233
   PubMedGoogle Scholar
• Aarli J. A., Tonder O. Effect of antiepileptic drugs on serum and salivary IgA. Scand. J. Immunol. 1975; 4: 391
   PubMed Web of Science ®Google Scholar
• Seager J., Jamison D. L., Wilson J., Hayward A. R., Soothill J. F. IgA deficiency, epilepsy and phenytoin treatment. Lancet 1975; 2: 632
   PubMedGoogle Scholar
• Gilhus N. E., Matre R., Aarli J. A. Lymphocyte subpopulations and lymphocyte function in phenytoin-treated patients with epilepsy. Int. J. Immunopharmac. 1982; 4: 43
   PubMedGoogle Scholar
• Ricevuti G., Marcoli M., Gatti G., Mazzone A., Lecchini S., Frigo G. M. Assessment of polymorphonuclear leukocyte functions in adult epileptic patients undergoing long-term phenytoin treatment. Hum. Toxicol. 1986; 5: 237
   PubMedGoogle Scholar
• Guerra I. C., Fawcett W. A., Redmon A. H., Lawrence E. C., Rosenblatt H. M., Shearer W. T. Permanent intrinsic B cell immunodeficiency caused by phenytoin hypersensitivity. J. Allergy Clin. Immunol. 1986; 77: 603
   PubMed Web of Science ®Google Scholar
• Abratt A. P., Sealy R., Uys C. J., Lawson R. Lymphadenopathy associated with diphenylhydantoin therapy. Clin. Oncol. 1982; 8: 351
   PubMedGoogle Scholar
• Rosenthal C. J., Noguera C. A., Coppola A., Kapelner S. N. Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation. Cancer 1982; 49: 2305
   PubMed Web of Science ®Google Scholar
• Aymard J. P., Lederlin P., Witz F., Colomb J. N., Faure G., Guerci O., Herbeuval R. Multiple myeloma after phenytoin therapy. Scand. J. Haematol. 1981; 26: 330
   PubMedGoogle Scholar
• Uetrecht J. P., Woosley R. L. Acetylator phenotype and lupus erythematosus. Clin. Pharmacokin. 1981; 6: 118
   PubMed Web of Science ®Google Scholar
• Wallace D. J., Dubois E. L. Dubois' Lupus Erythematosus. Lea & Febiger, Philadelphia 1987
   Google Scholar
• Levo Y., Pick A. I., Avidor I., Ben-Bassat M. Clinico-pathological study of a patient with procainamide-induced systemic lupus erythematosus. Ann. Rheum. Dis. 1976; 35: 181
   PubMedGoogle Scholar
• Whittle T. S., Ainsworth S. K. Procainamide-induced systemic lupus erythematosus. Arch. Pathol, Lab. Med. 1976; 100: 469
   PubMed Web of Science ®Google Scholar
• Zech P., Colon S., Labeeuw M., Bernheim J., Blanc-Brunat N. Nephrotic syndrome in procainamide induced lupus. Clin. Nephrol. 1979; 11: 218
   PubMedGoogle Scholar
• Foucar E., Erickson D. G., Tung K. S. K. Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature. J. Clin. Lab. Immunol. 1979; 2: 79
   PubMedGoogle Scholar
• Uetrecht J. P. Mechanism of drug-induced lupus. Chem. Res. Toxicol. 1988; 1: 133
   PubMed Web of Science ®Google Scholar
• Reidenberg M. M. Aromatic amines and the pathogenesis of lupus erythematosus. Am. J. Med. 1983; 75: 1037
   PubMed Web of Science ®Google Scholar
• Reidenberg M. M., Durant P. J., Harris R. A., De Boccardo G., Lahita R., Stenzel K. H. Lupus erythematosus-like disease due to hydrazine. Am. J. Med. 1983; 75: 365
   PubMed Web of Science ®Google Scholar
• Malinow M. R., Bardana E. J., Pirofsky B., Craig S., McLaughlin P. Systemic lupus erythematosus-like syndrome in monkeys fed alfalfa sprouts: role of a nonprotein amino acid. Science 1982; 216: 415
   PubMed Web of Science ®Google Scholar
• Isenberg D. A., Dudeney C., Williams W., Todd-Pokropek A., Stollar B. D. Disease activity in systemic lupus erythematosus related to a range of antibodies binding DNA and synthetic polynucleotides. Ann. Rheum. Dis. 1988; 47: 717
   PubMedGoogle Scholar
• Fritzler M. J., Tan E. M. Antibodies to histones in druginduced and idiopathic lupus erythematosus. J. Clin. Invest. 1978; 62: 560
   PubMed Web of Science ®Google Scholar
• Portanova J. P., Rubin R. L., Joslin F. G., Agnello V. D., Tan E. M. Reactivity of anti-histone antibodies induced by procainamide and hydralazine. Clin. Immunol. Immunopathol 1982; 25: 67
   PubMedGoogle Scholar
• Gohill J., Fritzler M. J. Antibodies in procainamide-induced and systemic lupus erythematosus bind the C-terminus of histone 1 (H1). Mol. Immunol. 1987; 24: 275
   PubMed Web of Science ®Google Scholar
• Portanova J. P., Arndt R. E., Tan E. M., Kotzin B. L. Anti-histone antibodies in idiopathic and drug-induced lupus recognize distinct intrahistone regions. J. Immunol. 1987; 138: 446
   PubMed Web of Science ®Google Scholar
• Totoritis M. C., Tan E. M., McNally E. M., Rubin R. L. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N. Engl. J. Med. 1988; 318: 1431
   PubMed Web of Science ®Google Scholar
• Schwartz R. S., Stollar B. D. Origins of anti-DNA autoantibodies. J. Clin. Invest. 1985; 75: 321
   PubMed Web of Science ®Google Scholar
• Harkiss G. D., Hendrie F. M., Thompson D. Anti-Klebsiella K30 phospholipid antibodies in systemic lupus erythematosus: antigen cross-reactions and idiotypic sharing with antibodies to DNA andKlebsiella K30 polysaccharide. J. Clin. Immunol. 1988; 8: 319
   PubMedGoogle Scholar
• Pincus T., Schur P. H., Rose J. A., Decker J. L., Talal N. Measurement of serum DNA-binding activity in systemic lupus erythematosus. N. Engl. J. Med. 1969; 281: 701
   PubMed Web of Science ®Google Scholar
• Blomgren S. E., Condemi J. J., Bignall M. C., Vaughan J. H. Antinuclear antibody induced by procainamide: a prospective study. N. Engl. J. Med. 1969; 281: 64
   PubMed Web of Science ®Google Scholar
• Woosley R. L., Drayer D. E., Reidenberg M. M., Nies A. S., Carr K., Oates J. A. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N. Engl. J. Med. 1978; 298: 1157
   PubMed Web of Science ®Google Scholar
• Henningsen N. C., Cederberg A., Hanson A., Johansson B. W. Effects of long-term treatment with procaine amide. Acta Med. Scand. 1975; 198: 475
   PubMed Web of Science ®Google Scholar
• Lahita R., Kluger J., Drayer D. E., Koffler D., Reidenberg M. M. Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide. N. Engl. J. Med. 1979; 301: 1382
   PubMed Web of Science ®Google Scholar
• Roden D. M., Reele S. B., Higgins S. B., Wilkinson G. R., Smith R. F., Oates J. A., Woosley R. L. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am. J. Cardiol 1980; 46: 463
   PubMed Web of Science ®Google Scholar
• Stec G. P., Lertora J. J. L., Atkinson A. J., Nevin M. J., Kushner W., Jones C., Schmid F. R., Askenazi J. Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy. Ann. Intern. Med. 1979; 90: 799
   PubMed Web of Science ®Google Scholar
• Kluger J., Drayer D. E., Reidenberg M. M., Lahita R. Acetylprocainamide therapy in patients with previous procainamide-induced lupus syndrome. Ann. Intern. Med. 1981; 95: 18
   PubMedGoogle Scholar
• Uetrecht J. P., Sweetman B. J., Woosley R. L., Oates J. A. Metabolism of procainamide to a hydroxylamine by rat and human hepatic microsomes. Drug Metab. Dispos. 1984; 12: 77
   PubMed Web of Science ®Google Scholar
• Freeman R. W., Uetrecht J. P., Woosley R. L., Oates J. A., Harbison R. D. Covalent binding of procainamidein vitro to hepatic protein in mice. Drug Metab. Dispos. 1981; 9: 188
   PubMed Web of Science ®Google Scholar
• Uetrecht J. P. Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J. Pharmacol. Exp. Ther. 1985; 232: 420
   PubMed Web of Science ®Google Scholar
• Rubin R. L., Uetrecht J. P., Jones J. E. Cytotoxicity of oxidative metabolites of procainamide. J. Pharmacol. Exp. Ther. 1987; 242: 833
   PubMed Web of Science ®Google Scholar
• Uetrecht J., Zahid N., Rubin R. Metabolism of procainamide to a hydroxylamine by human neutrophils and mononuclear leukocytes. Chem. Res. Toxicol. 1988; 1: 74
   PubMed Web of Science ®Google Scholar
• Klebanoff S. J., Clark R. A. The Neutrophil: Function and Clinical Disorders. North-Holland, New York 1978
   Google Scholar
• Sberra A. J., Strauss R. R. The Respiratory Burst and Its Physiological Significance. Plenum Press, New York 1988
   Google Scholar
• Van Furth R. Mononuclear Phagocytes: Functional Aspects. Martinus Nijhoff, The Hague 1980
   Google Scholar
• Harrison J., Araiso T., Palcic M., Dunford H. Compound I of myeloperoxidase. Biochem. Biophys. Res. Commun. 1980; 94: 34
   PubMed Web of Science ®Google Scholar
• Winterborn C. Comparative reactives of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to hypochlorite. Biochim. Biophys. Acta 1985; 840: 204
   PubMedGoogle Scholar
• Hammerschmidt D. E. Activation of the complement system and of granulocytes in lung injury: the adult respiratory distress syndrome. Advances in Inflammation Research, G. Weissmann. Raven Press, New York 1983; 147
   Google Scholar
• Johnson R. J., Couser W. G., Chi E. Y., Adler S., Klebanoff S. New mechanism for glomerular injury: myeloperoxidase-hydrogen peroxide-halide system. J. Clin. Invest. 1987; 79: 1379
   PubMed Web of Science ®Google Scholar
• Ichihara S., Tomisawa H., Fukazawa H., Tateishi M. Involvement of leukocyte peroxidases in the metabolism of tenoxicam. Biochem. Pharmacol. 1985; 34: 1337
   PubMed Web of Science ®Google Scholar
• Ichihara S., Tomisawa H., Fukazawa H., Tateishi M., Joly R., Heintz R. Involvement of leukocytes in the oxygenation and chlorination reaction of phenylbutazone. Biochem. Pharmacol. 1986; 35: 3935
   PubMed Web of Science ®Google Scholar
• Tsuruta Y., Subrahmanyam V. V., Marhsall W., O'Brien P. J. Peroxidase-mediated irreversible binding of arylamine carcinogens to DNA in intact polymorphonuclear leukocytes activated by a tumor promoter. Chem.-Biol. Interact. 1985; 53: 25
   PubMed Web of Science ®Google Scholar
• Uetrecht J., Zahid N. Procainamide (PA) is N-chlorinated by myeloperoxidase (MPO) — implications for toxicity. Pharmacologist 1988; 30: A98
   Google Scholar
• Werdelin O., Mouritsen S., Peterson B. L., Sette A., Buus S. Facts on the fragmentation of antigens in presenting cells, on the association of antigen fragments with MHC molecules in cell-free systems, and speculation on the cell biology of antigen processing. Immunol. Rev. 1988; 106: 181
   PubMedGoogle Scholar
• Francoeur A., Heitzmann J. G. Autoantibodies: terms and concepts. Clin. Immunol. Immunopathol. 1988; 47: 245
   PubMedGoogle Scholar
• Andersen M. R., Atkin C. L., Eyre H. J. Intact form of myeloperoxidase from normal human neutrophils. Arch. Biochem. Biophys. 1982; 214: 273
   PubMed Web of Science ®Google Scholar
• Murao S., Stevens F. J., Ito A., Huberman E. Myeloperoxidase: a myeloid cell nuclear antigen with DNA-binding properties. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 1232
   PubMed Web of Science ®Google Scholar
• Gorsulowsky D. C., Bank P. W., Goldberg A. D., Lee T. G., Heinzerling R. H., Burnham T. K. Antinuclear antibodies as indicators for the procainamide-induced systemic lupus erythematosus-like syndrome and its clinical presentations. J. Am. Acad. Dermatol. 1985; 12: 245
   PubMed Web of Science ®Google Scholar
• Falk R. J., Jennette J. C. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N. Engl. J. Med. 1988; 318: 1651
   PubMed Web of Science ®Google Scholar
• Weller P. F., Ackerman S. J., Smith J. A. Eosinophil granule cationic proteins: major basic protein is distinct from the smaller subunit of eosinophil peroxidase. J. Leukocyte Biol. 1988; 43: 1
   PubMedGoogle Scholar
• Hoffman B. J. Sensitivity to sulfadiazine resembling acute lupus erythematosus. Arch. Dermatol. Syph. 1945; 51: 190
   Google Scholar
• Uetrecht J. P., Shear N., Biggar W. Dapsone is metabolised by human neutrophils to a hydroxylamine. Pharmacologist 1986; 28: 239
   Google Scholar
• Uetrecht J. Unpublished observation
   Google Scholar
• Salama A., Mueller-Eckhardt C. The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. N. Engl. J. Med. 1985; 313: 469
   PubMed Web of Science ®Google Scholar
• Garcia-Morteo O., Maldonado-Cocco J. A. Lupus-like syndrome during treatment with nomifensine. Arthritis Rheum. 1983; 26: 936
   PubMed Web of Science ®Google Scholar
• McCraken M., Benson E. A., Hickling P. Systemic lupus erythematosus induced by aminoglutethimide. Br. Med. J. 1980; 281: 1254
   PubMed Web of Science ®Google Scholar
• Raftery E. B., Denman A. M. Systemic lupus erythematosus syndrome induced by practolol. Br. Med. J. 1973; 2: 452
   PubMed Web of Science ®Google Scholar
• Stewart M. W., Clarke S. W. Practolol-induced SLE-like syndrome. Proc. R. Soc. Med. 1976; 69: 61
   PubMedGoogle Scholar
• Milner G. R., Holt P. J. L., Bottomley J., Maciver J. E. Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII. J. Clin. Pathol. 1977; 30: 770
   PubMed Web of Science ®Google Scholar
• Cody R. J., Calabrese L. H., Clough J. D., Tarari R. C., Bravo E. L. Development of antinuclear antibodies during acebutolol therapy. Clin. Pharmacol. Ther. 1979; 25: 800
   PubMed Web of Science ®Google Scholar
• Booth R. J., Bullock J. Y., Wilson J. D. Antinuclear antibodies in patients on acebutolol. Br. J. Clin. Pharmacol. 1980; 9: 515
   PubMed Web of Science ®Google Scholar
• Harrison T., Sisca T. S., Wood W. H. Propranolol-induced lupus syndrome. Postgrad. Med. 1976; 59: 241
   PubMed Web of Science ®Google Scholar
• Wilson J. D., Bullock J. Y., Sutherland D. C., Main C., O'Brien K. P. Antinuclear antibodies in patients receiving non-practolol beta-blockers. Br. Med. J. 1978; 1: 14
   PubMed Web of Science ®Google Scholar
• Booth R. J., Wilson J. D., Bullock J. Y. β-Adrenergicreceptor blockers and antinuclear antibodies in hypertension. Clin. Pharmacol. Ther. 1982; 31: 555
   PubMed Web of Science ®Google Scholar
• Sutherland D. C., Wilson J. D. Practolol and the safety of other beta blockers. N.Z. Med. J. 1976; 84: 282
   PubMedGoogle Scholar
• Amos H. E., Lake B. G., Artis J. Possible role of antibody specific for practolol metabolite in the pathogenesis of oculomucocutaneous syndrome. Br. Med. J. 1978; 1: 402
   PubMed Web of Science ®Google Scholar
• Amos H. E. Immunological aspects of practolol toxicity. Int. J. Immunopharmac. 1979; 1: 9
   PubMedGoogle Scholar
• Griffiths I. D., Kane S. P. Sulphasalazine-induced lupus syndrome in ulcerative colitis. Br. Med. J. 1977; 2: 1188
   PubMed Web of Science ®Google Scholar
• Vanheule B. A., Carswell F. Sulphasalazine-induced systemic lupus erythematosus in a child. Eur. J. Pediatr. 1983; 140: 66
   PubMed Web of Science ®Google Scholar
• Uetrecht J., Zahid N., Shear N. H., Biggar W. D. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J. Pharmacol. Exp. Ther. 1988; 245: 274
   PubMed Web of Science ®Google Scholar
• Vandersteen P. R., Jordan R. E. Dermatitis herpetiformis with discoid lupus erythematosus: occurrence of sulfone-induced discoid lupus erythematosus. Arch. Dermatol 1974; 110: 95
   PubMed Web of Science ®Google Scholar
• Perry H. M. Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am. J. Med. 1973; 54: 58
   PubMed Web of Science ®Google Scholar
• Cameron H. A., Ramsay L. E. The lupus syndrome induced by hydralazine: a common complication with low dose therapy. Br. Med. J. 1984; 289: 410
   PubMed Web of Science ®Google Scholar
• Harland S. J., Facchini V., Timbrell J. A. Hydrallazine-induced lupus erythematosus-like syndrome in a patient of the rapid acetylator phenotype. Br. Med. J. 1980; 281: 273
   PubMedGoogle Scholar
• Hofstra A., Uetrecht J. Oxidation of hydralazine by monocytes as a mechanism of hydralazine-induced lupus. Pharmacologist 1988; 30: A99
   Google Scholar
• Timbrell J. A., Facchini V., Harland S. J., Mansilla-Tinoco R. Hydralazine-induced lupus: is there a toxic pathway. Eur. J. Clin. Pharmacol. 1984; 27: 555
   PubMed Web of Science ®Google Scholar
• Li A., Uetrecht J. Metabolism of isoniazid by activated neutrophils. Pharmacologist 1988; 30: A99
   Google Scholar
• Engler H., Taurog A., Nakashima T. Mechanism of inactivation of thyroid peroxidase by thioureylene drugs. Biochem. Pharmacol. 1982; 31: 3801
   PubMed Web of Science ®Google Scholar
• Engler H., Taurog A., Luthy C., Dorris M. Reversible and irreversible inhibition of thyroid peroxidase-catalyzed iodination by thioureylene drugs. Endocrinology 1983; 112: 86
   PubMed Web of Science ®Google Scholar
• Imamura M., Aoki N., Saito T., Ohno Y., Maruyama Y., Yamaguchi J., Yamamoto T. Inhibitory effects of antithyroid drugs on oxygen radical formation in human neutrophils. Acta Endocrinol. 1986; 112: 210
   PubMedGoogle Scholar
• Lee E., Miki Y., Hosokawa M., Sayo H., Kariya K. Oxidative metabolism of propylthiouracil by peroxidases from rat bone marrow. Xenobiotica 1988; 18: 1135
   PubMed Web of Science ®Google Scholar
• Waldhauser L., Uetrecht J. Propylthiouracil (PTU) is metabolized by activated neutrophils — implications for agranulocytosis. FASEB J. 1988; 2: A1134
   Google Scholar
• Amrhein J. A., Kenny F. M., Ross D. Granulocytopenia, lupus-like syndrome, and other complications of propylthiouracil therapy. J. Pediatr. 1970; 76: 54
   PubMed Web of Science ®Google Scholar
• Berkman E. M., Orlin J. B., Wolfsdorf J. An anti-neutrophil antibody associated with a propylthiouracil-induced lupus-like syndrome. Transfusion 1983; 23: 135
   PubMed Web of Science ®Google Scholar
• Takuwa N., Kojima I., Ogata E. Lupus-like syndrome — a rare complication in thionamide treatment for Graves' disease. Endocrinol. Jpn. 1981; 28: 663
   PubMedGoogle Scholar
• Aucoin D. P., Peterson M. E., Hurvitz A. I., Drayer D. E., Lahita R. G., Quimby F. W., Reidenberg M. M. Propylthiouracil-induced immune-mediated disease in the cat. J. Pharmacol. Exp. Ther. 1985; 234: 13
   PubMed Web of Science ®Google Scholar
• Aucoin D. P., Rubin R. L., Peterson M. E., Reidenberg M. M., Drayer D. E., Hurvitz A. I., Lahita R. G. Dose-dependent induction of anti-native DNA antibodies in cats by propylthiouracil. Arthritis Rheum. 1988; 31: 688
   PubMed Web of Science ®Google Scholar
• Farbman K., Wheeler M. F., Glick S. M. Arthritis induced by antithyroid medication. N.Y. State J. Med. 1969; 69: 826
   PubMedGoogle Scholar
• Kurtz M. D. Migratory polyarthritis occurring with methimazole therapy. N.Y. State J. Med. 1968; 68: 2810
   PubMedGoogle Scholar
• Reidenberg M. M., Case D. B., Drayer D. E., Reis S., Lorenzo B. Development of antinuclear antibody in patients treated with high doses of captopril. Arthritis Rheum. 1984; 27: 579
   PubMed Web of Science ®Google Scholar
• Patri P., Nigro A., Rebora A. Lupus erythematosus-like eruption from captopril. Acta Dermatol. Venereal. 1985; 65: 447
   PubMed Web of Science ®Google Scholar
• Harkcom T. M., Conn D. L., Holley K. E. d-Penicillamine and lupus erythematosus-like syndrome. Ann. Intern. Med. 1978; 89: 1012
   PubMed Web of Science ®Google Scholar
• Chalmers A., Thompson D., Stein H. E., Reid G., Patterson A. C. Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis. Ann. Intern. Med. 1982; 97: 659
   PubMed Web of Science ®Google Scholar
• Netter P., Bannwarth B., Faure G., Trechot P., Royer R. J. Adverse effects of d-penicillamine. A cooperative study by the French regional drug surveillance centers. J. Rheumatol. 1988; 15: 1730
   PubMedGoogle Scholar
• Benton J. W., Tynes B., Register H. B., Alford C., Holley H. L. Systemic lupus erythematosus occurring during anticonvulsive drug therapy. JAMA 1962; 180: 115
   Web of Science ®Google Scholar
• Beernink D. H., Miller J. J. Anticonvulsant-induced antinu-clear antibodies and lupus-like disease in children. J. Pediatr. 1973; 82: 113
   PubMed Web of Science ®Google Scholar
• Singsen B. H., Fishman L., Hanson V. Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants. Pediatrics 1976; 57: 529
   PubMed Web of Science ®Google Scholar
• Gleichmann H. Systemic lupus erythematosus triggered by diphenylhydantoin. Arthritis Rheum. 1982; 25: 1387
   Google Scholar
• Claesen M., Moustafa M. A. A., Adline J., Vandervorst D., Poupaert J. H. Evidence for an arene oxide-NIH shift pathway in the metabolic conversion of phenytoin to 5-(4-hydroxyphenyl)-5-phenylhydantoin in the rat and man. Drug Metab. Dispos. 1982; 10: 667
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano P. R. Oxygen activation and transfer. Cytochrome P-450: Structure, Mechanism, and Biochemistry, P. R. Ortiz de Montellano. Plenum Press, New York 1986; 217
   Google Scholar
• Pantarotto C., Arboix M., Sezzano P., Abbruzzi R. Studies on 5,5-diphenylhydantoin irreversible binding to rat liver microsomal proteins. Biochem. Pharmacol. 1982; 31: 1501
   PubMed Web of Science ®Google Scholar
• Spielberg S. P., Gordon G. B., Blake D. A., Mellits E. D., Bross D. S. Anticonvulsant toxicity in vitro: possible role of arene oxides. J. Pharmacol. Exp. Ther. 1981; 217: 386
   PubMed Web of Science ®Google Scholar
• Kupferberg H. J. Other hydantoins: mephenytoin and ethotoin. Antiepileptic Drugs, D. M. Woodbury, J. K. Penry, C. E. Pippenger. Raven Press, New York 1982; 283
   Google Scholar
• Muller-Kuppers M. Zur frage der fruchtschadigung in der sehwangerschaft durch einnahme von antiepileptica. Acta Paedopsychiatry 1963; 30: 401
   PubMedGoogle Scholar
• Kupfer A., Roberts R. K., Schenker S., Branch R. A. Stereoselective metabolism of mephenytoin in man. J. Pharmacol. Exp. Ther. 1981; 218: 193
   PubMed Web of Science ®Google Scholar
• Wells P. G., Kupfer A., Lawson J. A., Harbison R. D. Relation ofin vivo drug metabolism to stereoselective hydantoin toxicity in mouse: evaluation of mephenytoin and its metabolite, nirvanol. J. Pharmacol. Exp. Ther. 1982; 221: 228
   PubMed Web of Science ®Google Scholar
• Feldman G. L., Weaver D. D., Lovrien E. W. The fetal trimethadione syndrome: report of an additional family and further delineation of this syndrome, Am. J. Dis. Child. 1977; 131: 1389
   PubMedGoogle Scholar
• Dreifuss F. E. Ethosuximide. Antiepileptic Drugs, D. M. Woodbury, J. K. Penry, C. E. Pippenger. Raven Press, New York 1982; 647
   Google Scholar
• Dabbous I. A., Idriss H. M. Occurrence of systemic lupus erythematosus in association with ethosuximide therapy. J. Pediatr. 1970; 76: 617
   PubMedGoogle Scholar
• Teoh P. C., Chan H. L. Lupus-scleroderma syndrome induced by ethosuximide. Arch. Dis. Child. 1975; 50: 658
   PubMed Web of Science ®Google Scholar
• Rall T. W., Schleifer L. S. Drugs effective in the therapy of epilepsies. Goodman and Gilman's the Pharmacological Basis of Therapeutics, A. G. Gilman, L. S. Goodman, T. W. Rail, F. Murad. Macmillan, New York 1985; 446
   Google Scholar
• Uetrecht J., Zahid N. N-Chlorination of phenytoin by myeloperoxidase to a reactive metabolite. Chem. Res. Toxicol. 1988; 1: 148
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D., Fishbein E., Reyes P. A., Dies H., Shwadsky S. Antinuclear antibodies in patients on anticonvulsant therapy. Clin. Exp. Immunol. 1972; 12: 39
   PubMed Web of Science ®Google Scholar
• Simpson J. R. “Collagen disease” due to carbamazepine (Tegretol). Br. Med. J. 1966; 2: 1434
   PubMedGoogle Scholar
• Bateman D. E. Carbamazepine induced systemic lupus erythematosus: case report. Br. Med. J. 1985; 291: 632
   PubMed Web of Science ®Google Scholar
• Alballa S., Fritzler M., Davis P. A case of drug induced lupus due to carbamazepine. J. Rheumatol. 1987; 14: 599
   PubMed Web of Science ®Google Scholar
• Livingston S., Villamater C., Sakata Y., Pauli L. L. Use of carbamazepine in epilepsy. JAMA 1967; 200: 204
   PubMed Web of Science ®Google Scholar
• Killian J. M. Tegretol in trigeminal neuralgia with special reference to hemopoietic side effects. Headache 1969; 9: 58
   PubMedGoogle Scholar
• Livingston S., Pauli L. L., Berman W. Carbamazepine (Tegretol) in epilepsy. Dis. Nerv. Syst. 1974; 35: 103
   PubMedGoogle Scholar
• Rosenow E. C. Drug-induced bronchopulmonary pleural disease. J. Allergy Clin. Immunol. 1987; 80: 780
   PubMedGoogle Scholar
• Severson G. S., Harrington D. S., Burnett D. A., Linder J. Dermatopathic lymphadenopathy associated with carbamazepine: a case mimicking a lymphoid malignancy. Am. J. Med. 1987; 83: 597
   PubMed Web of Science ®Google Scholar
• Luchins D. J. Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine. Am. J. Psychiatry 1984; 141: 687
   PubMedGoogle Scholar
• Shear N. H., Spielberg S. P. Anticonvulsant hypersensitivity syndrome. J. Clin. Invest. 1988; 82: 1826
   PubMed Web of Science ®Google Scholar
• Lewis I. J., Rosenbloom L. Glandular fever-like syndrome, pulmonary eosinophilia and asthma associated with carbamazepine. Postgrad. Med. J. 1982; 58: 100
   PubMedGoogle Scholar
• Hart R. G., Easton J. D. Carbamazepine and hematological monitoring. Ann. Neurol. 1982; 11: 309
   PubMed Web of Science ®Google Scholar
• Horler A. R. Blood disorders. Textbook of Adverse Drug Reactions, D. M. Davies. Oxford University Press, Oxford 1985; 578
   Google Scholar
• Pisciotta V. Drug-induced agranulocytosis. Drugs 1978; 15: 132
   PubMed Web of Science ®Google Scholar
• Ellrodt A. G., Murata G. H., Reidinger M. S., Stewart M. E., Mochizuki C., Gray R. Severe neutropenia associated with sustained-release procainamide. Ann. Intern. Med. 1984; 100: 197
   PubMed Web of Science ®Google Scholar
• Meyers D. G., Gonzalez E. R., Peters L. L., Davis R. B., Feagler J. R., Egan J. D., Nair C. K. Severe neutropenia associated with procainamide: comparison of sustained and conventional preparations. Am. Heart J. 1985; 109: 1393
   PubMed Web of Science ®Google Scholar
• Thompson J. F., Robinson C. A., Segal J. L. Procainamide agranulocytosis: a case report and review of the literature. Curr. Ther. Res. 1988; 44: 872
   Web of Science ®Google Scholar
• Vincent P. C. Drug-induced aplastic anaemia and agranulocytosis: incidence and mechanisms. Drugs 1986; 31: 52
   PubMed Web of Science ®Google Scholar
• Heit W., Heimpel H., Fischer A., Frickhofen N. Drug-induced agranulocytosis: evidence for commitment of bone marrow haematopoiesis. Scand. J. Haematol. 1985; 35: 459
   PubMedGoogle Scholar
• Pisciotta A. V. Immune and toxic mechanisms in drug-induced agranulocytosis. Semin. Hematol. 1973; 10: 279
   PubMed Web of Science ®Google Scholar
• Azocar J. Anti-myeloid-cell antibody in procainamide-induced agranulocytosis. Lancet 1984; 1: 1069
   PubMedGoogle Scholar
• Berger B., Hauser D. Agranulocytosis due to new sustained-release procainamide. Am. Heart J. 1983; 105: 1035
   PubMedGoogle Scholar
• Bluming A. Z., Plotkin D., Rosen P., Thiessen R. Severe transient pancytopenia associated with procainamide ingestion. JAMA 1976; 236: 2520
   PubMed Web of Science ®Google Scholar
• Nelson J. C., Lutton J. D., Fass A. E. Procainamide-induced agranulocytosis with reversible myeloid sensitivity. Am. J. Hematol. 1984; 17: 427
   PubMedGoogle Scholar
• Rothman I. K., Amorosi E. L. Procainamide-induced agranulocytosis and thrombocytopenia. Arch. Intern. Med. 1979; 139: 246
   PubMed Web of Science ®Google Scholar
• Wang R. I. H., Schuller G. Agranulocytosis following procainamide administration. Am. Heart J. 1969; 78: 282
   PubMed Web of Science ®Google Scholar
• Weitzman S. A., Stossel T. P. Drug-induced immunological neutropenia. Lancet 1978; 1: 1068
   PubMed Web of Science ®Google Scholar
• Shields A. F., Berenson J. A. Procainamide-associated pancytopenia. Am. J. Hematol 1988; 27: 299
   PubMed Web of Science ®Google Scholar
• Kleinman S., Nelson R., Smith L., Goldfinger D. Positive direct antiglobulin tests and immune hemolytic anemia in patients receiving procainamide. N. Engl. J. Med. 1984; 311: 809
   PubMed Web of Science ®Google Scholar
• Firkin F. C., Mariani A. F. Agranulocytosis due to dapsone. Med. J. Aust. 1977; 2: 247
   PubMedGoogle Scholar
• Levine P. H., Weintraub L. R. Pseudoleukemia during recovery from dapsone-induced agranulocytosis. Ann. Intern. Med. 1968; 68: 1060
   PubMed Web of Science ®Google Scholar
• Wilson J. R., Harris J. W. Hematologic side-effects of dapsone. Ohio State Med. J. 1977; 73: 557
   PubMedGoogle Scholar
• Potter M. N., Yates P., Slade R., Kennedy C. T. C. Agranulocytosis caused by dapsone therapy for granuloma annulare. J. Am. Acad. Dermatol. 1989; 20: 87
   PubMedGoogle Scholar
• Ognibene A. J. Agranulocytosis due to dapsone. Ann. Intern. Med. 1970; 72: 521
   PubMed Web of Science ®Google Scholar
• Weetman R. M., Boxer L. A., Brown M. P., Mantich N. M., Baehner R. L. In vitro inhibition of granulopoiesis by 4-amino-4′-hydroxylaminodiphenyl sulfone. Br. J. Haematol. 1980; 45: 361
   PubMed Web of Science ®Google Scholar
• Rinkoff S. S., Spring M. Toxic depression of the myeloid elements following therapy with the sulfonamides: report of 8 cases. Ann. Intern. Med. 1941; 15: 89
   Google Scholar
• Arneborn P., Palmblad J. Drug-induced neutropenia in the Stockholm region 1973–75. Acta Med. Scand. 1978; 204: 283
   PubMed Web of Science ®Google Scholar
• Arneborn P., Palmblad J. Drug-induced neutropenias in the Stockholm region 1976–1977. Acta Med. Scand. 1979; 206: 241
   PubMed Web of Science ®Google Scholar
• Sheehan J. Trimethoprim-associated marrow toxicity. Lancet 1981; 2: 692
   PubMedGoogle Scholar
• Asmar B. I., Maqbool S., Dajani A. S. Hematologic abnormalities after oral trimethoprim-sulfamethoxazole therapy in children. Am. J. Dis. Child. 1981; 135: 1100
   PubMedGoogle Scholar
• Lawrence B., Santen R. J., Lipton A., Harvey H. A., Hamilton R., Mercurio T. Pancytopenia induced by aminoglutethimide in the treatment of breast cancer. Cancer Treat. Rep. 1978; 62: 1581
   PubMedGoogle Scholar
• Gez E., Sulkes A. Aminoglutethimide-induced leucopenia: a case report and review of the literature. Oncology 1984; 41: 399
   PubMed Web of Science ®Google Scholar
• Lonning P. E., Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 1988; 35: 685
   PubMed Web of Science ®Google Scholar
• Harvey R. L., Luzar M. J. Metoclopramide-induced agranulocytosis. Ann. Intern. Med. 1988; 108: 214
   PubMed Web of Science ®Google Scholar
• Manoharan A. Metoclopramide-induced agranulocytosis. Med. J. Aust. 1988; 149: 508
   PubMedGoogle Scholar
• Rab S. M., Alam M. N. Severe agranulocytosis during paraaminosalicylic acid therapy. Br. J. Dis. Chest 1970; 64: 164
   PubMedGoogle Scholar
• Das K. M., Eastwood M. A., McManus J. P. A., Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N. Engl. J. Med. 1973; 289: 491
   PubMed Web of Science ®Google Scholar
• Jacobson I. M., Kelsey P. B., Blyden G. T., Demirjian Z. N., Isselbacher K. J. Sulfasalazine-induced agranulocytosis. Am. J. Gastroenterol. 1985; 80: 118
   PubMed Web of Science ®Google Scholar
• Wheelan K. R., Cooper B., Stone M. J. Multiple hematologic abnormalities associated with sulfasalazine. Ann. Intern. Med. 1982; 97: 726
   PubMedGoogle Scholar
• Abrams S. M., Degnan T. J., Vinceguerra V. Marrow aplasia following topical application of chloramphenicol eye ointment. Arch. Intern. Med. 1980; 140: 576
   PubMed Web of Science ®Google Scholar
• Keiser G. Cooperative study of patients treated with thiamphenicol. Comparative study of patients treated with chloramphenicol and thiamphenicol. Postgrad. Med. J. 1974; 50: 143
   PubMed Web of Science ®Google Scholar
• Manyan D. R., Arimura G. K., Yunis A. A. Comparative metabolic effects of chloramphenicol analogues. Mol. Pharmacol. 1975; 11: 520
   PubMed Web of Science ®Google Scholar
• Scheline R. R. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol. Rev. 1973; 25: 451
   PubMed Web of Science ®Google Scholar
• Ascherl M., Eyer P., Kampffmeyer H. Formation and disposition of nitrosochloramphenicol in rat liver. Biochem. Pharmacol. 1985; 34: 3755
   PubMed Web of Science ®Google Scholar
• Yunis A. A., Miller A. M., Salem Z., Corbett M. D., Arimura G. K. Nitroso-chloramphenicol: possible mediator in chloramphenicol-induced aplastic anemia. J. Lab. Clin. Med. 1980; 96: 36
   PubMed Web of Science ®Google Scholar
• Gross B. J., Branchflower R. V., Burke T. R., Lees D. E., Pohl L. R. Bone marrow toxicity in vitro of chloramphenicol and its metabolites. Toxicol. Appl. Pharmacol. 1982; 64: 557
   PubMed Web of Science ®Google Scholar
• Jimenez J. J., Arimura G. K., Abou-Khalil W. H., Isildar M., Yunis A. A. Chloramphenicol-induced bone marrow injury: possible role of bacterial metabolites of chloramphenicol. Blood 1987; 70: 1180
   PubMed Web of Science ®Google Scholar
• Isildar M., Abou-Khalil W. H., Jimenez J. J., Abou-Khalil A., Yunis A. A. Aerobic nitroreduction of dehydrochloramphenicol by bone marrow. Toxicol. Appl. Pharmacol. 1988; 94: 305
   PubMed Web of Science ®Google Scholar
• Bilezikian S. B., Laleli Y., Tsan M., Hodkinson B. A., Ice S., McIntyre P. A. Immunological reactions involving leukocytes. III. Agranulocytosis induced by antithyroid drugs. Johns Hopkins Med. J. 1976; 138: 124
   PubMedGoogle Scholar
• Guffy M. M., Goeken N. E., Burns C. P. Granulocytotoxic antibodies in a patient with propylthiouracil-induced agranulocytosis. Arch. Intern. Med. 1984; 144: 1687
   PubMed Web of Science ®Google Scholar
• Wall J. R., Fang S. L., Kuroki T., Ingbar S. H., Braverman L. E. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis. J. Clin. Endocrinol. Metab. 1984; 58: 868
   PubMed Web of Science ®Google Scholar
• Fibbe W. E., Claas F. H. J., Van der Star-Dijlistra W., Schaafsma M. R., Meyboom R. H. B., Falkenburg J. H. F. Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. Br. J. Haematol. 1986; 64: 363
   PubMed Web of Science ®Google Scholar
• Toth E. L., Mant M. J., Shamim S., Ginsberg J. Propylthiouracil-induced agranulocytosis: an unusual presentation and a possible mechanism. Am. J. Med. 1988; 85: 725
   PubMed Web of Science ®Google Scholar
• Moreb J., Shemesh O., Shilo S., Manor C., Hershko S. Transient methimazole-induced bone marrow aplasia: in vitro evidence for a humoral mechanism of bone marrow suppression. Acta Haematol 1983; 69: 127
   PubMed Web of Science ®Google Scholar
• Amann F. W., Buhler F. R., Conen D., Brunner F., Ritz R., Speck B. Captopril-associated agranulocytosis. Lancet 1980; 1: 150
   PubMed Web of Science ®Google Scholar
• Van Brununelen P., Willemze R., Tan W. D., Thompson J. Captopril-associated agranulocytosis. Lancet 1980; 1: 150
   Google Scholar
• Forslund T., Borgmastars H., Fyhrquist F. Captopril-associated leukopenia confirmed by rechallenge in patient with renal failure. Lancet 1981; 1: 166
   PubMed Web of Science ®Google Scholar
• Hammond W. P., Miller J. E., Starkebaum G., Zweerink H. J., Rosenthal A. S., Dale D. C. Suppression of in vitro granulocytopoiesis by captopril and penicillamine. Exp. Hematol. 1988; 16: 674
   PubMed Web of Science ®Google Scholar
• Cuthbert M. F. Adverse reactions to non-steroidal antirheumatic drugs. Curr. Med. Res. Opinion 1974; 2: 600
   PubMed Web of Science ®Google Scholar
• Feldman E. J., Isenberg J. I. Effects of metiamide on gastric acid hypersecretion, steatorrhea and bone-marrow function in a patient with systemic mastocytosis. N. Engl. J. Med. 1976; 295: 1178
   PubMed Web of Science ®Google Scholar
• Fleischer D., Samloff I. M. Cimetidine therapy in a patient with metiamide-induced agranulocytosis. N. Engl. J. Med. 1977; 296: 342
   PubMedGoogle Scholar
• Pisciotta A. V. Phenytoin: hematological toxicity. Antiepileptic Drugs, D. M. Woodbury. Raven Press, New York 1982; 257
   Google Scholar
• Taetle R., Lane T. A., Mendelsohn J. Drug-induced agranulocytosis:in vitro evidence for immune suppression of granulopoiesis and a cross-reacting lymphocyte antibody. Blood. 1979; 54: 501
   PubMed Web of Science ®Google Scholar
• Abbott J. A., Schwab R. S. The serious side effects of the newer antiepileptic drugs: their control and prevention. N. Engl. J. Med. 1950; 242: 943
   PubMedGoogle Scholar
• Dessypris E. N., Redline S., Harris J. W., Krantz S. B. Diphenylhydantoin-induced pure red cell aplasia. Blood. 1985; 65: 789
   PubMed Web of Science ®Google Scholar
• Inman W. H. W. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Br. Med. J. 1977; 1: 1500
   PubMed Web of Science ®Google Scholar
• International Agranulocytosis and Aplastic Anemia Study. Risks of agranulocytosis and aplastic anemia: a first report with special reference to analgesics. JAMA 1986; 256: 1749
   PubMed Web of Science ®Google Scholar
• Weissmann G., Xefteris E. D. Phenylbutazone leukopenia. Arch. Intern. Med. 1959; 103: 957
   Web of Science ®Google Scholar
• Kadar D., Kalow W. Acute and latent leukopenic reaction to antipyrine. Clin. Pharmacol. Ther. 1980; 28: 820
   PubMedGoogle Scholar
• Servant D., Danel T., Goudemand M. Lithium therapy in carbamazepine-induced agranulocytosis. Am. J. Psychiatry 1988; 145: 381
   PubMedGoogle Scholar
• Curson D. A., Hale A. S. Mianserin and agranulocytosis. Br. Med. J. 1979; 1: 378
   PubMed Web of Science ®Google Scholar
• McHarg A. M., McHarg J. F. Leukopenia in association with mianserin. Br. Med. J. 1979; 1: 623
   PubMed Web of Science ®Google Scholar
• Page C. E. Mianserin-induced agranulocytosis. Br. Med. J. 1982; 284: 1912
   PubMedGoogle Scholar
• Senn H. J., Jungi W. F., Kunz H., Poldinger W. Clozapine and agranulocytosis. Lancet. 1977; 1: 547
   PubMed Web of Science ®Google Scholar
• Idanpaan-Heikkila J., Alhava E., Olkinuora M., Palva I. P. Agranulocytosis during treatment with clozapine. Eur. J. Clin. Pharmacol. 1977; 11: 193
   PubMed Web of Science ®Google Scholar
• Mindham R. H. S. The major tranquilizers. Side Effects of Drugs Annual 2, M. N. G. Dukes. Excerpta Medica, Amsterdam 1978; 45
   Google Scholar
• Bigby M., Jick S., Jick H., Arndt K. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975–1982. JAMA 1986; 256: 3358
   PubMed Web of Science ®Google Scholar
• Lyell A. A review of toxic epidermal necrolysis in Britain. Br. J. Dermatol. 1967; 79: 662
   PubMed Web of Science ®Google Scholar
• Shear N. H., Spielberg S. P., Grant D. M., Tang B. K., Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann. Intern. Med. 1986; 105: 179
   PubMed Web of Science ®Google Scholar
• Rieder M. J., Uetrecht J., Shear N. H., Cannon M., Miller M., Spielberg S. P. Diagnosis of sulfonamide hypersensitivity reactions byin-vitro “rechallenge” with hydroxylamine metabolites. Ann. Intern. Med. 1989; 110: 286
   PubMed Web of Science ®Google Scholar
• Shear N. H., Spielberg S. P. In vitro evaluation of a toxic metabolite of sulfadiazine. Can. J. Physiol. Pharmacol. 1985; 63: 1370
   PubMed Web of Science ®Google Scholar
• Rieder M. J., Uetrecht J., Shear N. H., Spielberg S. P. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J. Pharmacol. Exp. Ther. 1988; 244: 724
   PubMed Web of Science ®Google Scholar
• Dujovne C. A., Chan C. H., Zimmerman H. J. Sulfonamide hepatic injury: review of the literature and report of a case due to sulfamethoxazole. N. Engl. J. Med. 1967; 277: 785
   PubMed Web of Science ®Google Scholar
• Harle D. G., Baldo B. A., Smal M. A., Van Nunen S. A. An immunoassay for the detection of IgE antibodies to trimethoprim in the sera of allergic patients. Clin. Allergy 1987; 17: 209
   PubMedGoogle Scholar
• Svanbom M., Rombo L., Gustafsson L. Unusual pulmonary reaction during short term prophylaxis with pyrimethamine-sulfadoxine (Fansidar). Br. Med. J. 1984; 288: 1876
   PubMedGoogle Scholar
• Selby C. D., Ladusans E. J., Smith P. G. Fatal multisystemic toxicity associated with prophylaxis with pyrimethamine and sulfadoxine (Fansidar). Br. Med. J. 1985; 290: 113
   PubMed Web of Science ®Google Scholar
• Pearl R. K., Nelson R. L., Prasad M. L., Orsay C. P., Abcarian H. Serious complications of sulfasalazine. Dis. Colon Rectum 1986; 29: 201
   PubMedGoogle Scholar
• Jones G. R., Malone D. N. S. Sulphasalazine induced lung disease. Thorax 1972; 27: 713
   PubMedGoogle Scholar
• Davies D., MacFarlane A. Fibrosing alveolitis and treatment with sulfasalazine. Gut 1974; 15: 185
   PubMedGoogle Scholar
• Thomas P., Seaton A., Edwards J. Respiratory disease due to sulfasalazine. Clin. Allergy 1974; 4: 41
   PubMedGoogle Scholar
• Tydd T. F., Dyer N. H. Sulphasalazine lung. Med. J. Aust. 1976; 1: 570
   PubMedGoogle Scholar
• Leickly F. E., Buckley R. H. Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy. Clin. Lab. Obser. 1986; 108: 481
   Google Scholar
• Powers N. G., Carson S. H. Idiosyncratic reactions to phenytoin. Clin. Pediatr. 1987; 26: 120
   PubMedGoogle Scholar
• Kahn H. D., Faguet G. B., Agee J. F., Middleton H. M. Drug-induced liver injury:in vitro demonstration of hypersensitivity to both phenytoin and phenobarbital. Arch. Intern. Med. 1984; 144: 1677
   PubMedGoogle Scholar
• Taylor J. W., Stein M. N., Murphy M. J., Mitros F. A. Cholestatic liver dysfunction after long-term phenytoin therapy. Arch. Neurology 1984; 41: 500
   PubMedGoogle Scholar
• Aaron J. S., Bank S., Ackert G. Diphenylhydantoin-induced hepatotoxicity. Am. J. Gastroenterol 1985; 80: 200
   PubMedGoogle Scholar
• Brown M., Schubert T. Phenytoin hypersensitivity hepatitis and mononucleosis syndrome. J. Clin. Gastroenterol. 1986; 8: 469
   PubMedGoogle Scholar
• Gaffey C. M., Chun B., Harvey J. C., Manz H. J. Phenytoin-induced systemic granulomatous vasculitis. Arch. Pathol. Lab. Med. 1986; 110: 131
   PubMed Web of Science ®Google Scholar
• Chamberlain D. W., Hyland R. H., Ross D. J. Diphenylhydantoin-induced lymphocytic interstitial pneumonia. Chest 1986; 90: 458
   PubMedGoogle Scholar
• Spielberg S. P., Gordon G. B., Blake D. A., Goldstein D. A., Herlong H. F. Predisposition to phenytoin hepatotoxicity assessed. in vitro, N. Engl. J. Med. 1981; 305: 722
   PubMed Web of Science ®Google Scholar
• Frey H. M., Gershon A. A., Bordowsky W., Bullock W. E. Fatal reaction to dapsone during treatment of leprosy. Ann. Intern. Med. 1981; 94: 777
   PubMed Web of Science ®Google Scholar
• Kromann N. P., Vilhelmsen R., Stahl D. The dapsone syndrome. Arch. Dermatol 1982; 118: 531
   PubMed Web of Science ®Google Scholar
• Wille R. C., Morrow J. D. Case report: Dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider. Am. J. Med. Sci. 1988; 296: 270
   PubMed Web of Science ®Google Scholar
• Grossman S. J., Jollow D. J. Role of dapsone hydroxylamine in dapsone-induced hemolytic anemia. J. Pharmacol. Exp. Ther. 1988; 244: 118
   PubMed Web of Science ®Google Scholar
• Jones G. W., George T. L., Bradley R. D. Procainamide-induced hemolytic anemia. Transfusion 1978; 18: 224
   PubMed Web of Science ®Google Scholar
• Rotmensch H. H., Yust I., Siegman-Igra Y., Liron M., Ilie B., Vardinon N. Granulomatous hepatitis: a hypersensitivity response to procainamide. Ann. Intern. Med. 1978; 89: 646
   PubMedGoogle Scholar
• Houston B. D., Crouch M. E., Brick J. E., DiBartolomeo A. G. Apparent vasculitis associated with propylthiouracil use. Arthritis Rheum. 1979; 22: 925
   PubMed Web of Science ®Google Scholar
• Vasily D. B., Tyler W. B. Propylthiouracil-induced cutaneous vasculitis: case presentation and review of the literature. JAMA 1980; 243: 458
   PubMed Web of Science ®Google Scholar
• Carrasco M. D., Riera C., Clotet B., Grifol M., Foz M. Cutaneous vasculitis associated with propylthiouracil therapy. Arch. Intern. Med. 1987; 147: 1677
   PubMed Web of Science ®Google Scholar
• Mihas A. A., Holley P., Koff R. S., Hirschowitz B. I. Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil. Gastroenterology 1976; 70: 770
   PubMed Web of Science ®Google Scholar
• Coleman J. W., Yeung J. H. K., Roberts D. H., Breckenridge A. M., Park B. K. Drug-specific antibodies in patients receiving captopril. Br. J. Clin. Pharm. 1986; 22: 161
   PubMed Web of Science ®Google Scholar
• Peterson H. Association of trimethadione therapy and myastenia gravis. N. Engl. J. Med. 1966; 274: 506
   PubMedGoogle Scholar
• Haynes R. C., Murad F. Thyroid and antithyroid drugs. Goodman and Gilman's the Pharmacological Basis of Therapeutics, A. G. Gilman, L. S. Goodman, T. W. Rall, F. Murad. Macmillan, New York 1985; 1389
   Google Scholar
• Takayama S., Aihara K., Onodera T., Akimoto T. Antithyroid effects of propylthiouracil and sulfamonomethoxine in rats and monkeys. Toxicol. Appl. Pharmacol 1986; 82: 191
   PubMed Web of Science ®Google Scholar
• Smellie J. M., Bantock H. M., Thompson B. D. Co-trimoxazole and the thyroid. Lancet 1982; 2: 96
   PubMedGoogle Scholar
• Hughes S. W. M., Burley D. M. Aminoglutethimide: a ‘side-effect’ turned to therapeutic advantage. Postgrad. Med. J. 1970; 46: 409
   PubMed Web of Science ®Google Scholar
• Brown C. G., Fowler K. L., Nicholls P. J., Atterwill C. Assessment of thyrotoxicity usingin vitro cell culture systems. Food Chem. Toxicol 1986; 24: 557
   PubMedGoogle Scholar
• Griciute L., Tomatis L. Carcinogenicity of dapsone in mice and rats. Int. J. Cancer 1980; 25: 123
   PubMedGoogle Scholar
• Nishiyama S., Matsukura M., Fujimoto S., Matsuda I. Reports of two cases of autoimmune thyroiditis while receiving anticonvulsant therapy. Eur. J. Pediatr. 1983; 140: 116
   PubMed Web of Science ®Google Scholar
• Gupta A., Waldhauser L., Reider M., Harper P., Daneman D., Eggo M., Shear N., Uetrecht J., Spielberg S. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions. Soc. Pediatr. Res. 1988; 23: 277
   Google Scholar
• Lang P. G. Sulfones and sulfonamides in dermatology today. J. Am. Acad. Dermatol 1979; 1: 479
   PubMed Web of Science ®Google Scholar
• Bernstein J. E., Lorincz A. L. Sulfonamides and sulfones in dermatologic therapy. Int. J. Dermatol 1981; 20: 81
   PubMedGoogle Scholar
• Katz S. I. Commentary: sulfoxone (diasone) in the treatment of dermatitis herpetiformis. Arch. Dermatol 1982; 118: 809
   Google Scholar
• Swinson D. R., Zlosnick J., Jackson L. Double-blind trial of dapsone against placebo in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 1981; 40: 235
   PubMedGoogle Scholar
• Grindulis K. A., McConkey B. Rheumatoid arthritis: the effects of treatment with dapsone on hemoglobin. J. Rheumatol. 1984; 11: 776
   PubMed Web of Science ®Google Scholar
• Stendahl O., Molin L., Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone: a possible mechanism in the treatment of dermatitis herpetiformis. J. Clin. Invest. 1978; 62: 214
   PubMed Web of Science ®Google Scholar
• Wozel G., Barth J. Current aspects of modes of action of dapsone. Int. J. Dermatol 1988; 27: 547
   PubMedGoogle Scholar
• Klotz U., Mauer K., Fischer C., Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N. Engl. J. Med. 1980; 303: 1499
   PubMed Web of Science ®Google Scholar
• Dull B. J., Salata K., Van Langenhove A., Goldman P. 5-Aminosalicylate: oxidation by activated leukocytes and protection of cultured cells from oxidative damage. Biochem. Pharmacol. 1987; 36: 2467
   PubMed Web of Science ®Google Scholar
• Craven P. A., Pfanstiel J., Saito R., DeRubertis F. R. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity. Gastroenterology 1987; 92: 1998
   PubMed Web of Science ®Google Scholar
• Miyachi Y., Yoshioka A., Imamura S., Niwa Y. Effect of sulfasalazine and its metabolites on the generation of reactive oxygen species. Gut 1987; 28: 190
   PubMed Web of Science ®Google Scholar
• Hallgren R., Colombel J. F., Dahl R., Fredens K., Kruse A., Jacobsen N. O., Venge P., Rambaud J. C. Neutrophil and eosinophil involvement of the small bowel in patients with celiac disease and Crohn's disease: studies on the secretion rate and immuno-histochemical localization of granulocyte granule constituents. Am. J. Med. 1989; 86: 56
   PubMed Web of Science ®Google Scholar
• Neumann V. C., Taggart A. J., Le Gallez P., Astbury C., Hill J., Bird H. A. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. J. Rheumatol. 1986; 13: 285
   PubMed Web of Science ®Google Scholar
• Pinals R. S., Kaplan S. B., Lawson J. G., Hepburn B. Sulfasalazine in rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum. 1986; 29: 1427
   PubMedGoogle Scholar
• Cuperus R. A., Muijsers A. O., Wever R. Antiarthritic drugs containing thiol groups scavenge hypochlorite and inhibit its formation by myeloperoxidase from human leukocytes: a therapeutic mechanism of these drugs in rheumatoid arthritis. Arthritis Rheum. 1985; 28: 1228
   PubMed Web of Science ®Google Scholar
• Wasil M., Halliwell B., Morehouse C. P., Hutchison D. C. S., Baum H. Biologically-significant scavenging of the myelope-roxidase-derived oxidant hypochlorous acid by some anti-inflammatory drugs. Biochem. Pharmacol. 1987; 36: 3847
   PubMed Web of Science ®Google Scholar
• Walzer C., Frenk E. Cytochemical expression of epidermal peroxidase and cytochrome oxidase activities in pathological skin conditions of man. Arch. Dermatol. Res. 1986; 278: 460
   PubMedGoogle Scholar
• Khalaf M. R., Hayhoe F. G. J. Cytochemical demonstration of ‘platelet’ peroxidase at the light microscope level. Eur. J. Haematol. 1987; 39: 128
   PubMed Web of Science ®Google Scholar